OBI Pharma to Showcase Research Achievements and Cutting Edge ADC Platform Technology Frequent Speaking Engagements at Prestigious International Conferences
2024.Oct.27
Corporate
Sustainability
OBI Pharma and Fu Jen Catholic University Sign Industry-Academia Collaboration MOU Advancing Biotechnology Innovation and Developing Young Talent
2024.Oct.27
Corporate
Sustainability
OBI volunteers at a breast cancer patient event Showcasing our commitment to patients and to new drug development.
2024.Oct.13
Corporate
Ascentawits Pharma announced the interim analysis results of the AST-3424 Phase II clinical efficacy and safety study in advanced HCC at the 2024 CSCO conference
2024.Sep.24
Corporate
Award & Certification
OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards
2024.Aug.22
Corporate
The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs
2024.Aug.07
Corporate
OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer
2024.Jul.30
Corporate
OBI Pharma: An Exciting Launching Pad for Young Scientists
2024.Jul.29
Corporate
OBI’s Proprietary ADC Platform GlycOBI® Seeks Collaborative Partnerships for Development